Entertainment

I-Mab Reports Third Quarter 2024 Results

I-Mab Biopharma

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study ofuliledlimab in first-line mNSCLC in 1H 2025

Home Previous 52 53 54 55 56 57 58 Next Tail

10 Items Per Page (Page 55 / 129) Total 1282 Items

©copyright 2009-2020 Danger Daily      Contact Us   SiteMap